文献速递淋巴瘤

评价同种异体与自体膜结合型IL-21扩增NK细胞用于慢性淋巴细胞白血病治疗

Evaluation of allogeneic and autologous membrane-bound IL-21-expanded NK cells for chronic lymphocytic leukemia therapy.
PubMed 文献 · Blood Adv · 2022-01-01

研究显示健康供者与慢性淋巴细胞白血病(CLL)患者来源的NK细胞经表达膜结合型白细胞介素-21(mbIL-21)的饲养细胞刺激后快速扩增,并对同种异体或自体CLL细胞具有强细胞毒活性;与抗CD20抗体联用可显著增强NK细胞对CLL靶细胞的识别与杀伤;在2种人CLL异种移植小鼠模型中验证了体内疗效,支持将mbIL-21扩增NK细胞与奥妥珠单抗及维奈克拉联合用于CLL治疗。

要点

  • mbIL-21扩增的NK细胞对同种异体或自体CLL细胞均有强细胞毒活性。
  • 与抗CD20抗体联用可显著增强NK细胞对CLL靶细胞的识别与杀伤。
  • 伊布替尼对扩增NK细胞呈混合的抑制与保护效应,而扩增NK细胞对维奈克拉高度耐药。

核心结论

  • 数据支持开发mbIL-21扩增NK细胞联合CD20抗体奥妥珠单抗与维奈克拉用于CLL治疗。

研究设计与样本

  • 体外研究:健康供者来源与CLL患者来源的NK细胞经表达mbIL-21的饲养细胞刺激扩增,并检测其对同种异体或自体CLL细胞的细胞毒活性。
  • 体内研究:在2种人CLL异种移植小鼠模型中评估疗效。

主要发现

  • 健康供者来源和CLL患者来源的NK细胞经mbIL-21饲养细胞刺激后均快速扩增。
  • 扩增后的NK细胞对同种异体或自体CLL细胞具有强细胞毒活性。
  • 与抗CD20抗体联用可显著增强NK细胞对CLL靶细胞的识别与杀伤。
  • 伊布替尼对扩增NK细胞呈混合的抑制与保护效应,扩增NK细胞对维奈克拉高度耐药。
  • 在2种人CLL异种移植小鼠模型中显示体内疗效,支持在维奈克拉与奥妥珠单抗方案基础上联合mbIL-21扩增NK细胞。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Successes with anti-CD20 antibodies in chronic lymphocytic leukemia (CLL) and enhanced activity of Fc-engineered vs unmodified antibody therapy suggest a potentially impactful role for natural killer (NK) cells and other innate immune cells in controlling this disease. Stimulated NK cells have shown promise as a cellular therapy, but their application has been constrained by limited expansion capacity and low cytotoxic activity against CLL cells. Here, we demonstrate that both healthy donor-derived and CLL patient-derived NK cells expand rapidly when stimulated with feeder cells expressing membrane-bound interleukin-21 (mbIL-21) and have potent cytotoxic activity against allogeneic or autologous CLL cells. Combination with anti-CD20 antibodies significantly enhances NK recognition and killing of CLL targets. As any CLL immune therapy would likely be given in combination, we assess commonly used treatments and demonstrate that ibrutinib has mixed suppressive and protective effects on expanded NK cells, whereas expanded NKs are highly resistant to venetoclax. We demonstrate efficacy in vivo in 2 xenograft mouse models of human CLL that support building upon a regimen of venetoclax and obinutuzumab with mbIL-21-expanded NK cells. Collectively, these data support development of mbIL-21-expanded NKs combined with the CD20 antibody obinutuzumab and venetoclax in the treatment of CLL.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Yano M, Sharpe C, Lance JR, et al. Evaluation of allogeneic and autologous membrane-bound IL-21-expanded NK cells for chronic lymphocytic leukemia therapy. Blood Adv. 2022. PMID: 35486482. doi:10.1182/bloodadvances.2021005883

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。